<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two children of 9 and 10 years suffering from severe systemic <z:hpo ids='HP_0005681'>juvenile rheumatoid arthritis</z:hpo> were treated intravenously with high-dose human immunoglobulin </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment was performed every 4 weeks for 7 and 18 months, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Improvement of arthritic symptoms was demonstrable by significant decreases of Ritchie index and number of swollen joints and the disappearance of heated joints in one patient </plain></SENT>
<SENT sid="3" pm="."><plain>The other patient was free of arthritic symptoms since the introduction of immunoglobulin therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical symptoms of <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic illness</z:e> were markedly improved and no relapse was seen </plain></SENT>
<SENT sid="5" pm="."><plain>Laboratory parameters also improved, including erythrocyte sedimentation rate, C-reactive protein, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, and serum iron levels </plain></SENT>
<SENT sid="6" pm="."><plain>Parallel investigations of immunological parameters revealed a decrease of serum Il-1 beta and Il-6 levels and a diminished in vitro production of Il-1 beta, Il-6, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, we suggest a decreased activation status of the monocyte-macrophage system as one possible mode of action </plain></SENT>
</text></document>